Curis inc (CRIS)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11
Cash Flows from Operating Activities:
Cash flows from operating activities:
Net loss

-9,700

-8,608

-6,436

-7,213

-9,884

-5,941

-7,223

-8,664

-10,747

-8,028

-15,457

-14,090

-15,742

-11,334

-28,346

-11,289

-9,442

-13,461

-5,543

-8,128

-31,848

-5,689

-5,580

-1,895

-5,563

-4,198

-1,867

-1,293

-4,962

-12,371

-3,385

-2,886

2,225

6,061

-4,206

-4,914

-6,800

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

25

28

30

32

35

61

40

46

53

24

63

58

55

52

51

56

34

38

41

40

41

40

39

37

37

37

36

33

34

35

30

30

30

30

31

24

21

Non-cash lease expense

149

283

225

208

240

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Stock-based compensation expense

625

692

684

631

651

631

894

1,189

1,226

1,379

1,292

1,585

1,103

1,014

1,631

908

772

1,000

901

1,022

951

814

818

683

743

503

922

915

660

785

807

1,007

1,022

420

311

361

677

Issuance of common stock in consideration for rights granted under the Aurigene collaboration agreement (see Note 3(b))

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-0

23,968

-

-

-

-

-

-

-

-

0

0

0

964

-

-

-

-

Change in fair value of warrant liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0

-67

-557

-91

-1,209

1,072

-333

-301

-

-

-

-

-

-

-

-

Amortization of debt issuance costs

0

0

0

0

8

10

9

7

9

9

7

9

119

12

12

12

12

12

13

12

18

20

16

26

26

26

26

26

26

-

-

-

-

-

-

-

-

Non-cash imputed interest expense related to the sale of future royalties

235

-

-

-

131

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash imputed interest expense related to the sale of future royalties

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Gain on disposal of assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1

18

-2

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of warrant liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,541

-495

7

-

587

-320

-1,501

Non-cash interest expense on investments

-25

13

3

52

-4

16

3

47

81

22

-18

39

10

-85

-74

-25

16

-30

-166

-259

306

-61

-39

-115

46

66

2

34

-197

209

126

40

58

53

-179

-17

-102

Gain (Loss) on Extinguishment of Debt

0

0

0

0

-3,495

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash interest expense on operating lease liability

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss on disposal of fixed assets

0

-

-1

-2

-5

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Payment-in kind interest on Curis Royalty's debt

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2

357

353

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash in-kind interest accrued on Curis Royalty's debt

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

171

246

335

-

-

-

-

-

-

-

-

Loss on disposal of fixed assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

17

23

5

31

Changes in operating assets and liabilities:
Accounts receivable

-737

347

763

348

-1,078

9

350

14

-582

617

225

36

-264

602

-12

123

-360

-212

225

323

-191

121

-3,004

3,474

-108

320

293

98

-143

-15

605

-21

297

-95

37

17

-10

Prepaid expenses, and other assets

248

-561

806

138

-146

-300

351

-133

-80

-169

201

-86

-213

-180

461

47

-243

387

65

-62

336

-166

300

-138

6

-9

91

14

19

247

-196

-28

-64

-307

305

15

-37

Accounts payable and accrued and other liabilities

-689

2,066

573

316

-2,895

40

-1,239

412

-1,086

-454

-1,978

3,204

-1,148

1,206

1,455

-396

50

1,698

230

287

-441

15

-49

554

-159

-254

302

576

-442

-149

443

-267

-5

321

212

30

-147

Operating lease liability

-166

-252

-251

-251

-247

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total adjustments

693

3,009

-1,446

1,722

2,651

1,001

-1,000

1,726

783

523

-1,024

4,867

596

1,947

20,763

435

1,455

2,598

1,060

1,342

24,089

996

3,495

-2,833

258

-1,314

2,145

1,317

634

-967

-795

1,274

1,711

2,626

-218

715

2,171

Net cash used in operating activities

-9,000

-5,600

-7,876

-5,491

-7,233

-4,940

-8,223

-6,938

-9,964

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-4,180

-1,611

3,937

8,688

-4,424

-4,198

-4,628

Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-15,146

-

-7,583

-10,854

-7,987

-

-4,483

-6,785

-7,759

-

-2,085

-4,729

-5,305

-5,512

277

23

-4,328

-

-

-

-

-

-

-

-

Cash flows from investing activities:
Cash flows from investing activities:
Purchases of investments

-

-

-

-

-

596

5,213

4,186

16,746

6,830

16,815

14,920

12,556

7,154

1,741

19,277

29,467

27,645

29,299

8,734

57,561

3,114

12,936

11,959

13,388

21,919

16,203

17,616

10,088

25,197

13,792

8,421

21,742

9,900

6,625

6,746

18,864

Sales and maturities of investments

5,082

2,100

4,350

0

600

5,250

9,900

18,000

15,050

4,300

21,771

8,982

12,626

21,276

21,980

24,652

20,184

43,301

32,078

24,460

16,983

8,395

13,617

18,919

16,816

16,009

10,242

14,724

11,372

13,522

12,440

6,184

14,065

3,841

15,895

6,125

25,972

Decrease in restricted cash/investments

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-0

-13

-0

0

0

-13

0

0

0

-13

0

0

0

-41

0

-41

0

-219

Purchase of property and equipment

241

0

0

41

0

0

8

0

77

41

21

74

52

60

13

248

8

0

33

0

14

-

-

-

-

18

99

0

34

62

8

23

10

10

3

206

39

Proceeds from sale of fixed assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

17

23

5

31

Net cash provided by investing activities

4,841

1,549

1,453

-8,058

600

4,654

4,679

13,814

-1,773

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-1,359

-2,259

-7,645

-6,052

9,331

-823

7,319

Net cash (used in)/provided by investing activities

-

-

-

-

-

-

-

-

-

-

-

-

18

-

20,226

5,127

-9,291

-

2,765

15,725

-40,579

-

675

6,901

3,441

-5,928

-6,061

-2,891

1,263

-

-

-

-

-

-

-

-

Cash flows from financing activities:
Cash flows from financing activities:
Sale of common stock

3,000

-

-

-

0

-

-

-

-

-263

35,595

0

6,214

0

0

0

0

1

0

-240

64,859

-

-

-

-

12,731

325

2,891

297

139

416

1,273

3,275

450

46

693

601

Proceeds from royalty interest purchase agreement with Oberland Capital Management, LLC

0

0

0

0

65,000

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Payment of issuance costs on royalty interest purchase agreement

0

0

0

334

250

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from issuance of common stock under the Company’s stock-based compensation plans

-

-

-

-

-

-

-

-

-

118

130

426

464

1,746

463

628

70

1,003

8

66

128

26

0

76

180

-

-

-

-

-

-

-

-

-

-

-

-

Payment of liability of future royalties, net of imputed interest

1,723

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from new credit agreement with HealthCare Royalty

-

-

-

-

-

-

-

-

-

0

0

0

45,000

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Payment of debt issuance costs

-

-

-

-

-

-

-

-

-

0

0

0

192

0

0

0

0

-

-

-

-

-

-

-

-

0

0

0

261

-

-

-

-

-

-

-

-

Payment on termination of credit agreement with HealthCare Royalty Partners, III, L.P.

0

0

0

0

37,162

0

0

0

0

0

0

0

18,303

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Repayments of Debt

0

0

0

0

1,825

1,670

1,360

1,259

1,815

1,328

1,019

931

1,676

1,054

1,078

950

1,191

1,370

1,116

747

929

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by financing activities

1,277

-1,061

567

-1,998

25,763

-1,639

-1,360

-1,147

-1,815

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,260

1,273

3,275

599

185

693

601

Net decrease in cash and cash equivalents and restricted cash

-2,898

-5,111

-5,862

-15,547

19,130

-1,925

-4,904

5,729

-13,552

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Property and equipment purchases in accounts payable

26

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash (used in)/provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

31,507

-

-615

-322

-1,121

-

-1,108

-922

64,059

-

-813

76

180

7,253

9,819

2,891

36

-

-

-

-

-

-

-

-

Net (decrease)/increase in cash and cash equivalents

-

-

-

-

-

-

-

-

-

-11,549

23,160

-15,740

16,379

5,367

12,028

-6,049

-18,399

4,432

-2,826

8,017

15,720

-

-

-

-1,683

-4,187

4,035

23

-3,028

4,938

-4,280

-2,597

-432

3,235

5,092

-4,327

3,292

Property and equipment purchases in accounts payable

-

-

-

-

-

-

-

-

-

-

-

-174

174

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Receivable for issuances of common stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Supplemental cash flow data:
Cash paid for interest

1,062

-

-

-

948

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash commitment shares issued to Aspire Capital

900

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Unpaid and accrued equity issuance costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

240

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-